Literature DB >> 7792099

Induction of CD4+ and CD8+ T cell responses in efferent lymph responding to Toxoplasma gondii infection: analysis of phenotype and function.

E A Innes1, W R Panton, A Sanderson, K M Thomson, J M Wastling, S Maley, D Buxton.   

Abstract

The kinetics of induction of T cell responses were examined in efferent lymph from a node draining the site of a primary inoculation of Toxoplasma gondii. The numbers of T cells increased after infection, due initially to an expansion of the CD4+ T cell population followed by an increase in the number of CD8+ T cells which coincided with the peak lymphoblast response. Proliferative responses of CD4+ T cells to T. gondii antigen were detectable from day six after infection and immune efferent lymph cells inhibited the intracellular multiplication of T. gondii in vitro. Optimum inhibition was achieved using CD8+ T cells restimulated in vitro, and the effector function appeared to be directed preferentially against the autologous rather than the allogeneic infected target cell. The results provide unique information on the induction of immune responses to T. gondii in vivo and provide evidence that both CD4+ and CD8+ T cells are necessary for the development of protective immunity induced by the S48 strain of T. gondii which is used as a live vaccine in sheep.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7792099     DOI: 10.1111/j.1365-3024.1995.tb01017.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  10 in total

Review 1.  Local immune responses in afferent and efferent lymph.

Authors:  D M Haig; J Hopkins; H R Miller
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

2.  Mic1-3 Knockout Toxoplasma gondii is a good candidate for a vaccine against T. gondii-induced abortion in sheep.

Authors:  Marie-Noëlle Mévélec; Céline Ducournau; Alaa Bassuny Ismael; Michel Olivier; Edouard Sèche; Maryse Lebrun; Daniel Bout; Isabelle Dimier-Poisson
Journal:  Vet Res       Date:  2010-04-13       Impact factor: 3.683

3.  Fas-FasL interaction involved in pathogenesis of ocular toxoplasmosis in mice.

Authors:  M S Hu; J D Schwartzman; G R Yeaman; J Collins; R Seguin; I A Khan; L H Kasper
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

4.  Parasite distribution and associated immune response during the acute phase of Toxoplasma gondii infection in sheep.

Authors:  Delfien Verhelst; Stéphane De Craeye; Gary Entrican; Pierre Dorny; Eric Cox
Journal:  BMC Vet Res       Date:  2014-12-16       Impact factor: 2.741

Review 5.  T Cell Trafficking through Lymphatic Vessels.

Authors:  Morgan C Hunter; Alvaro Teijeira; Cornelia Halin
Journal:  Front Immunol       Date:  2016-12-21       Impact factor: 7.561

Review 6.  Key Limitations and New Insights Into the Toxoplasma gondii Parasite Stage Switching for Future Vaccine Development in Human, Livestock, and Cats.

Authors:  Marie-Noëlle Mévélec; Zineb Lakhrif; Isabelle Dimier-Poisson
Journal:  Front Cell Infect Microbiol       Date:  2020-11-25       Impact factor: 5.293

Review 7.  In Sickness and in Health: The Immunological Roles of the Lymphatic System.

Authors:  Louise A Johnson
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

Review 8.  Advances in vaccine development and the immune response against toxoplasmosis in sheep and goats.

Authors:  Tanjila Hasan; Yoshifumi Nishikawa
Journal:  Front Vet Sci       Date:  2022-08-25

Review 9.  A one health approach to vaccines against Toxoplasma gondii.

Authors:  Elisabeth A Innes; Clare Hamilton; Joao L Garcia; Andreas Chryssafidis; David Smith
Journal:  Food Waterborne Parasitol       Date:  2019-04-18

10.  Effective Nanoparticle-Based Nasal Vaccine Against Latent and Congenital Toxoplasmosis in Sheep.

Authors:  Céline Ducournau; Nathalie Moiré; Rodolphe Carpentier; Pauline Cantin; Clément Herkt; Isabelle Lantier; Didier Betbeder; Isabelle Dimier-Poisson
Journal:  Front Immunol       Date:  2020-09-09       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.